Ipca-Ranbaxy alliance receive USFDA nod for Metoclopramide tablets

New Delhi, Jun 17 (UNI) Ipca Laboratories Ltd today said it has secured approval from the US Food and Drug Administration (USFDA) for sale of its Metoclopramide Hydrochloride tablets.

''The total annual market sales of Metoclopramide HCL in the US is 27 billion dollars,'' the company said in a statement.

The company had earlier announced strategic alliance with Ranbaxy Pharmaceuticals Inc (Ranbaxy) based in Jacksonville, Florida (US) , a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), India's largest pharmaceutical company.

As a part of the agreement Ipca will manufacture and Ranbaxy will market this formulation in the US healthcare systems using Ipca's DMF approved Active Pharmaceutical Ingredient(API) -Metoclopramide.

The drug is used to treat nausea and vomiting, the statement added.

UNI AK KK BD1310